Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the year ended December 31, 2022.
finance News
PARIS – Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announces that it has entered into an exclusive, worldwide license agreement with SATT Conectus for the development and commercialization of a gene therapy candidate for the treatment of Fragile X...
LOS ANGELES – Mandos, LLC (Mandos) announced they have entered into an agreement with Vtesse, LLC, a wholly owned subsidiary of Mallinckrodt Pharmaceuticals (Mallinckrodt), a global biopharmaceutical company, to acquire adrabetadex (also known as VTS-270), a drug in development for the treatment of Niemann-Pick Type C1 disease (NPC1). This acquisition,...
NEW YORK, Sept. 10, 2021 /PRNewswire/ — Building on a commitment to educate clinicians on rare diseases, Medscape Education, a leading source of accredited medical education for healthcare professionals (HCPs), has launched Pathways In Rare Disease. This dedicated learning center serves as a centralized location for clinicians who are seeking information about how to...
Cambridge, MA – Merck bumped up its position from shareholder to acquirer in a move to scoop up neurodegenerative disease biotech Caraway Therapeutics for up to $610 million, the pharma giant announced Tuesday. Merck previously invested in Caraway in 2018 through its MRL Ventures Fund, Merck will now acquire all outstanding...
MUNICH, Germany – Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for Skysona™ (elivaldogene autotemcel, Lenti-D™), a product of bluebird bio, Inc. Today, the European Commission (EC) has granted marketing authorization for...
FOSTER CITY, Calif. & BEIJING – Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and CANbridge Pharmaceuticals, Inc., announced today that they have entered into a licensing agreement, pursuant to which CANbridge has agreed to develop and commercialize maralixibat in Greater China (China, Hong Kong, Macau and Taiwan). Maralixibat, an investigational, orally administered...
FOSTER CITY, Calif. – Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”) for $110 million. The PRV was granted by the U.S. Food and Drug Administration in...
This spring the Moebius Syndrome Foundation will award four educational scholarships of $2,000 each, to individuals who have Moebius syndrome and will be attending an undergraduate college/university/post-secondary vocational school. Three scholarships will be awarded to undergraduates and one to a graduate student! Applications must be received by April 30, 2021....
EAST LANSING, Mich. – Researchers at Michigan State University have teamed up to create a new way to image immune cells in living subjects that could enable new treatment opportunities and better outcomes for patients with Type 1 diabetes. In particular, the new approach could help bolster the success of...